Fourth quarter and full year 2022 results
Fourth quarter and full-year 2022 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
Featuring
Paul Hudson
Chief Executive Officer
Jean-Baptiste de Chatillon
Chief Financial Officer
Bill Sibold
Specialty Care
Olivier Charmeil
General Medicines
John Reed
R&D
Thomas Triomphe
Vaccines
Julie Van Ongevalle
Consumer Healthcare
Roy Papatheodorou
General Counsel
Highlights
With ten consecutive quarters of growth, the progress we’ve made in the past three years speaks for itself. As we launch the next phase of our strategy, our continued commitment to investing in the science will be crucial to maintaining a steady-state cadence of first and best in class medicines.
Paul Hudson
Chief Executive Officer, Sanofi